Skip to main content

Table 1 HbA1c (%) variability in the pooled empagliflozin and placebo arms separately, at week 28 and 52

From: Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial

  Number of patients Standard deviation
Median (IQR)
Coefficient of variation
Median (IQR)
Range
Median (IQR)
Week 28 Week 52 Week 28 Week 52 Week 28 Week 52 Week 28 Week 52
Placebo 2171 2112 0.3 (0.1, 0.6) 0.4 (0.3, 0.7) 3.9 (1.9, 6.8) 5.4 (3.6, 8.2) 0.4 (0.2, 0.8) 1.0 (0.6, 1.4)
Empagliflozin 4400 4304 0.2 (0.1, 0.4) 0.3 (0.2, 0.5) 3.1 (1.2, 5.8) 4.4 (3.0, 6.6) 0.3 (0.1, 0.6) 0.7 (0.5, 1.1)
p-value*     < 0.0001  < 0.0001  < 0.0001  < 0.0001  < 0.0001  < 0.0001
  1. p-value for difference between placebo and pooled empagliflozin arms. Only patients with at least two post-baseline HbA1c measurements up until week 28 or 52, respectively, are included
  2. * From Wilcoxon test
  3. IQR Inter-quartile-range